NEWS
Institutional Subscription: Comprehensive Analyses to Enhance Your Global and Local Impact
New Feature: Compare Your Institution with the Previous Year
Find a Professional: Explore Experts Across 197 Disciplines in 220 Countries!
Find a Professional
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
person
Find a Professional
Maria Teresa Bochicchio
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - / Italy
Medical and Health Sciences / Hematology
AD Scientific Index ID: 5042640
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Subject Leaders
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Maria Teresa Bochicchio's MOST POPULAR ARTICLES
1-)
Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain S Soverini, C De Benedittis, K Machova Polakova, A Brouckova, D Horner, ... Blood, The Journal of the American Society of Hematology 122 (9), 1634-1648, 2013 1762013
2-)
The BCR‐ABL1 transcript type influences response and outcome in P hiladelphia chromosome‐positive chronic myeloid leukemia patients treated frontline with imatinibF Castagnetti, G Gugliotta, M Breccia, A Iurlo, L Levato, F Albano, ...American journal of hematology 92 (8), 797-805, 20171052017
3-)
Differences among young adults, adults and elderly chronic myeloid leukemia patientsF Castagnetti, G Gugliotta, M Baccarani, M Breccia, G Specchia, L Levato, ...Annals of Oncology 26 (1), 185-192, 20151052015
4-)
Main changes in European clinical trials regulation (no 536/2014)E Tenti, G Simonetti, MT Bochicchio, G MartinelliContemporary clinical trials communications 11, 99-101, 2018572018
5-)
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemiaG Gugliotta, F Castagnetti, M Breccia, L Levato, M D’Adda, F Stagno, ...haematologica 100 (9), 1146, 2015472015
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept